Significant Ownership of Bain Capital Life Sciences Fund II, L.P.

Signature - Title
/s/ Andrew Hack - Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC
Location
Boston, MA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Bain Capital Life Sciences Fund II, L.P..

Notify me when Bain Capital Life Sciences Fund II, L.P. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Bain Capital Life Sciences Fund II, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SVRA Savara Inc. Common Stock, par value $0.001 per share 10% $55,969,975 17,600,621 Bain Capital Life Sciences Fund II, L.P. 25 Mar 2025
XLO Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share 8.5% $4,131,430 6,259,742 BCLS II Equity Opportunities, LP 31 Dec 2025
CCCC C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share 6.2% $13,453,200 6,060,000 BCLS II Equity Opportunities, LP 17 Oct 2025
MRSN Mersana Therapeutics, Inc. Common Stock, par value $0.0001 per share 0% $0 -$5,591,981 0 -100% Bain Capital Life Sciences Fund II, L.P. 06 Jan 2026

Schedules 13D/G Reported by Bain Capital Life Sciences Fund II, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.